Blood-based proteomic profiling of 251 inflammatory proteins in 543 newly diagnosed patients with acute myeloid leukemia (AML) identified an eight-protein signature that enhances risk stratification.

By treating them with oncostatin M, an inflammation-related protein, they achieved a million-fold cell expansion—far exceeding previous efforts. These organoids grew steadily for three months ...